Karenitecin
Neoplasm
Baylor College of MedicinePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
928 Active assets in the Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Vinorelbine Shi Yanxia | Phase 3 | BB |
LIDOCAINE Medical College of Wisconsin | Phase 4 | BB |
VITAMIN D Tanta University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Karenitecin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →